The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

被引：345

作者：

Zhang, Sen ^{[1
]}

Anjum, Rana ^{[1
]}

Squillace, Rachel ^{[1
]}

Nadworny, Sara ^{[1
]}

Zhou, Tianjun ^{[1
]}

Keats, Jeff ^{[1
]}

Ning, Yaoyu ^{[1
]}

Wardwell, Scott D. ^{[1
]}

Miller, David ^{[1
]}

Song, Youngchul ^{[1
]}

Eichinger, Lindsey ^{[1
]}

Moran, Lauren ^{[1
]}

Huang, Wei-Sheng ^{[1
]}

Liu, Shuangying ^{[1
]}

Zou, Dong ^{[1
]}

Wang, Yihan ^{[1
]}

Mohemmad, Qurish ^{[1
]}

Jang, Hyun Gyung ^{[1
]}

Ye, Emily ^{[1
]}

Narasimhan, Narayana ^{[1
]}

Wang, Frank ^{[1
]}

Miret, Juan ^{[1
]}

Zhu, Xiaotian ^{[1
]}

Clackson, Tim ^{[1
]}

Dalgarno, David ^{[1
]}

Shakespeare, William C. ^{[1
]}

Rivera, Victor M. ^{[1
]}

机构：

[1] ARIAD Pharmaceut Inc, Cambridge, MA USA

来源：

CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 22期

关键词：

ANAPLASTIC LYMPHOMA KINASE; CELL LUNG-CANCER; CRIZOTINIB RESISTANCE; NSCLC PATIENTS; MUTATIONS; DISCOVERY; DISEASE; CHEMOTHERAPY; PONATINIB; CERITINIB;

D O I：

10.1158/1078-0432.CCR-16-0569

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Purpose: Non-small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK(+)) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain. Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified. Here, we report the structure and first comprehensive preclinical evaluation of the next-generation ALK TKI brigatinib. Experimental Design: A kinase screen was performed to evaluate the selectivity profile of brigatinib. The cellular and in vivo activities of ALK TKIs were compared using engineered and cancer-derived cell lines. The brigatinib-ALK co-structure was determined. Results: Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases. Across a panel of ALK(+) cell lines, brigatinib inhibited native ALK (IC50, 10 nmol/L) with 12-fold greater potency than crizotinib. Superior efficacy of brigatinib was also observed in mice with ALK(+) tumors implanted subcutaneously or intracranially. Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clinically achievable concentrations. Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R. The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses. Conclusions: Brigatinib is a highly potent and selective ALK inhibitor. These findings provide the molecular basis for the promising activity being observed in ALK(+), crizotinib-resistant patients with NSCLC being treated with brigatinib in clinical trials. (C)2016 AACR.

引用

页码：5527 / 5538

页数：12

共 36 条

[1]

[Anonymous], BRIG DAT FIL

[2]

Brower M, 2014, 205755 US FOOD DRUG

[3]

Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma [J].

Ceccon, M. ;

Mologni, L. ;

Giudici, G. ;

Piazza, R. ;

Pirola, A. ;

Fontana, D. ;

Gambacorti-Passerini, C. .

MOLECULAR CANCER RESEARCH, 2015, 13 (04) :775-783

[4]

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias [J].

Cortes, J. E. ;

Kim, D. -W. ;

Pinilla-Ibarz, J. ;

le Coutre, P. ;

Paquette, R. ;

Chuah, C. ;

Nicolini, F. E. ;

Apperley, J. F. ;

Khoury, H. J. ;

Talpaz, M. ;

DiPersio, J. ;

DeAngelo, D. J. ;

Abruzzese, E. ;

Rea, D. ;

Baccarani, M. ;

Mueller, M. C. ;

Gambacorti-Passerini, C. ;

Wong, S. ;

Lustgarten, S. ;

Rivera, V. M. ;

Clackson, T. ;

Turner, C. D. ;

Haluska, F. G. ;

Guilhot, F. ;

Deininger, M. W. ;

Hochhaus, A. ;

Hughes, T. ;

Goldman, J. M. ;

Shah, N. P. ;

Kantarjian, H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) :1783-1796

[5]

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases [J].

Costa, Daniel B. ;

Shaw, Alice T. ;

Ou, Sai-Hong I. ;

Solomon, Benjamin J. ;

Riely, Gregory J. ;

Ahn, Myung-Ju ;

Zhou, Caicun ;

Shreeve, S. Martin ;

Selaru, Paulina ;

Polli, Anna ;

Schnell, Patrick ;

Wilner, Keith D. ;

Wiltshire, Robin ;

Camidge, D. Ross ;

Crino, Lucio .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1881-1888

[6]

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients [J].

Deininger, Michael W. ;

Hodgson, J. Graeme ;

Shah, Neil P. ;

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Nicolini, Franck E. ;

Talpaz, Moshe ;

Baccarani, Michele ;

Mueller, Martin C. ;

Li, Jin ;

Parker, Wendy T. ;

Lustgarten, Stephanie ;

Clackson, Tim ;

Haluska, Frank G. ;

Guilhot, Francois ;

Kantarjian, Hagop M. ;

Soverini, Simona ;

Hochhaus, Andreas ;

Hughes, Timothy P. ;

Rivera, Victor M. ;

Branford, Susan .

BLOOD, 2016, 127 (06) :703-712

[7]

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK [J].

Fontana, Diletta ;

Ceccon, Monica ;

Gambacorti-Passerini, Carlo ;

Mologni, Luca .

CANCER MEDICINE, 2015, 4 (07) :953-965

[8]

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer [J].

Friboulet, Luc ;

Li, Nanxin ;

Katayama, Ryohei ;

Lee, Christian C. ;

Gainor, Justin F. ;

Crystal, Adam S. ;

Michellys, Pierre-Yves ;

Awad, Mark M. ;

Yanagitani, Noriko ;

Kim, Sungjoon ;

Pferdekamper, AnneMarie C. ;

Li, Jie ;

Kasibhatla, Shailaja ;

Sun, Frank ;

Sun, Xiuying ;

Hua, Su ;

McNamara, Peter ;

Mahmood, Sidra ;

Lockerman, Elizabeth L. ;

Fujita, Naoya ;

Nishio, Makoto ;

Harris, Jennifer L. ;

Shaw, Alice T. ;

Engelman, Jeffrey A. .

CANCER DISCOVERY, 2014, 4 (06) :662-673

[9]

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study [J].

Gadgeel, Shirish M. ;

Gandhi, Leena ;

Riely, Gregory J. ;

Chiappori, Alberto A. ;

West, Howard L. ;

Azada, Michele C. ;

Morcos, Peter N. ;

Lee, Ruey-Min ;

Garcia, Linta ;

Yu, Li ;

Boisserie, Frederic ;

Di Laurenzio, Laura ;

Golding, Sophie ;

Sato, Jotaro ;

Yokoyama, Shumpei ;

Tanaka, Tomohiro ;

Ou, Sai-Hong Ignatius .

LANCET ONCOLOGY, 2014, 15 (10) :1119-1128

[10]

Gehrke BJ, 2011, 202570 CTR DRUG EV R

← 1 2 3 4 →